Investors flock to Glenmark Life Sciences Rp15bn IPO
Glenmark Life Sciences, a pharmaceutical ingredients manufacturer, wrapped up a three-day bookbuild for its India IPO on Thursday. The deal, worth up to Rp15.5bn ($208.6m), was covered 15.5 times.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: